Protect your high-risk patients against a devastating stroke/SE
with fewer critical site bleeding events vs warfarin11,12

Which of your high-risk patients could benefit from effective protection?

ROCKET AF. Efficacy analysis on the as-treated, per-protocol population during treatment. Safety analysis on safety population during treatment.
No significant difference in primary safety endpoint of major or clinically relevant non-major bleeding vs warfarin. Major GI bleed was more
common in the Xarelto® group (3.2%) vs warfarin group (2.2%, p<0.001).11,12